Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
32.10
+1.00 (3.22%)
Apr 22, 2026, 12:21 PM EDT - Market open
Surrozen Revenue
In the year 2025, Surrozen had annual revenue of $3.48M, down -67.37%. Surrozen had revenue of $528.00K in the quarter ending December 31, 2025, a decrease of -19.39%.
Revenue (ttm)
$3.48M
Revenue Growth
-67.37%
P/S Ratio
102.74
Revenue / Employee
$79,023
Employees
44
Market Cap
368.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.48M | -7.18M | -67.37% |
| Dec 31, 2024 | 10.66M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 12.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 228.37M |
| Niagen Bioscience | 129.42M |
| Enanta Pharmaceuticals | 66.98M |
| X4 Pharmaceuticals | 35.11M |
| Opus Genetics | 14.20M |
| Prelude Therapeutics | 12.14M |
| Ovid Therapeutics | 7.25M |
| Silence Therapeutics | 559.00K |
SRZN News
- 4 weeks ago - Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Surrozen to Present at Upcoming Healthcare Investor Conference - GlobeNewsWire
- 2 months ago - Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - Surrozen to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 5 months ago - Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 8 months ago - Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 months ago - Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 1 year ago - Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway - GlobeNewsWire